Clinical Focus

  • Obstetrics and Gynecology

Academic Appointments

  • Clinical Assistant Professor, Obstetrics & Gynecology
  • Clinical Assistant Professor (By courtesy), Pediatrics

Boards, Advisory Committees, Professional Organizations

  • Annual Clinical and Research Meeting Program Committee, North American Society for Pediatric & Adolescent Gynecology (2023 - Present)
  • Advocacy Committee, North American Society for Pediatric & Adolescent Gynecology (2022 - Present)

Professional Education

  • Board Certification: Royal College of Physicians and Surgeons of Canada, Obstetrics and Gynecology (2022)
  • Fellowship, Stanford Health Care, Pediatric & Adolescent Gynecology (2024)
  • Board Certification, American Board of Obstetrics and Gynecology (2023)
  • Residency, University of Toronto, Canada (2022)
  • Medical Education, Michael G. DeGroote School of Medicine, McMaster University, Canada (2017)

Contact

  • Academic
    okciuk@stanford.edu
    University - Academic staff Department: Gynecology and Gynecologic Specialties / Pediatric and Adolescent Gynecology Position: Clinical Assistant Professor
  • Clinical (Primary)  Stanford Children's Health Specialty Services Sunnyvale 1195 W Fremont Ave Sunnyvale, CA 94087 (669) 233-2872 (fax)

Additional Clinical Info

Additional Info

All Publications

  • Going with the flow: the emergence of menstrual science. BMJ sexual & reproductive health Tyson, N., Kciuk, O., Blumenthal, P. D. 2023

    View details for DOI 10.1136/bmjsrh-2023-201972

    View details for PubMedID 37643875

  • An adolescent with adnexal torsion presenting with severe hyponatremia JOURNAL OF PEDIATRIC SURGERY CASE REPORTS Brookhart, C., Kciuk, O., Debiec, K., Smith, C., Tyson, N. 2023; 92

    View details for DOI 10.1016/j.epsc.2023.102613

    View details for Web of Science ID 000956552000001

  • Progestins of today and tomorrow. Current opinion in obstetrics & gynecology Liu, S., Kciuk, O., Frank, M., Tyson, N. 2022

    Abstract

    PURPOSE OF REVIEW: To review the current literature on the multiple types and uses of progestins in reproductive healthcare.RECENT FINDINGS: Progestins for contraceptive use are available in multiple forms, with the ongoing development of transdermal, intravaginal, and male contraception formulations. Noncontraceptive use of progestins often overlaps with contraceptive indications, which allows for simultaneous multipurpose progestin use, especially in reproductive-aged patients. More studies are needed to determine contraceptive doses of progestins used for noncontraceptive purposes. Side effect profiles of progestins are dependent on their formulation and cross-reactivity with other steroid receptors. Development of newer progestins includes manipulating pharmacologic properties to avoid undesired side effects.SUMMARY: Progestins have multiple uses in reproductive healthcare, including contraception, menstrual suppression, endometrial protection, and hormonal replacement therapy. The development of progestins for these indications can expand therapy for people with contraindications to estrogen-based hormonal therapy.

    View details for DOI 10.1097/GCO.0000000000000819

    View details for PubMedID 36036464

  • Pelvic floor symptoms in cisgender women with Ehlers-Danlos syndrome: an international survey study INTERNATIONAL UROGYNECOLOGY JOURNAL Kciuk, O., Li, Q., Huszti, E., McDermott, C. D. 2022

    Abstract

    Ehlers-Danlos Syndrome (EDS) is a group of inherited connective tissue disorders associated with abnormal collagen, and is more prevalent in women than in men. The aim of this cross-sectional study was to characterize pelvic floor symptoms in cisgender women with EDS and to describe their impact on quality of life.An online questionnaire on obstetric and gynecological experiences of cisgender women with EDS was disseminated through EDS patient societies and social media. This study was a sub-analysis of the broader questionnaire and focused on pelvic floor disorders, whereby self-reported symptoms and validated questionnaires were used to assess pelvic floor symptom severity (Pelvic Floor Distress Inventory, PFDI-20), impact on quality of life (Pelvic Floor Impact Questionnaire, PFIQ-7), and sexual function (Female Sexual Function Index, FSFI-6). Groups based on age and EDS type were compared using Kruskal-Wallis and Chi-squared tests.A total of 1,303 participants were included in the analysis. Pelvic floor symptom prevalence included: stress urinary incontinence in 60%, urgency urinary incontinence in 54%, fecal incontinence in 24%, and pelvic organ prolapse in 21%. Bladder symptoms were reported to be the most bothersome. The impact of prolapse symptoms on quality of life was higher in women under age 40 than in older participants (p<0.001). Pelvic pain was reported in 71%. Pain ratings were highest for dysmenorrhea, muscle and joint pain, and backache (median 7 out of 10 for each). Almost half of participants screened positive for possible sexual dysfunction and 36% reported dyspareunia more than half the time.This large, observational study demonstrated that cisgender women with EDS report a high prevalence of pelvic floor symptoms that appear to be more severe than in the general population.

    View details for DOI 10.1007/s00192-022-05273-8

    View details for Web of Science ID 000815561000004

    View details for PubMedID 35751670

  • Painful periods in adolescents CANADIAN MEDICAL ASSOCIATION JOURNAL Kciuk, O., Kives, S. 2021; 193 (16): E560

    View details for DOI 10.1503/cmaj.201972

    View details for Web of Science ID 000645624200003

    View details for PubMedID 33875460

    View details for PubMedCentralID PMC8084563

https://orcid.org/0000-0002-8242-1663